New Drug Targets for HIV
Open Access
- 1 July 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (Supplement) , S96-S100
- https://doi.org/10.1086/429504
Abstract
A significant number of human immunodeficiency virus (HIV) infections have become resistant to antiretroviral treatment, which means that there is aKeywords
This publication has 19 references indexed in Scilit:
- Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolatesAIDS, 2004
- Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In VitroJournal of Virology, 2004
- Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus MacaquesScience, 2004
- Prospects of HIV‐1 entry inhibitors as novel therapeuticsReviews in Medical Virology, 2004
- Small-Molecule Antagonists of CCR5 and CXCR4: A Promising New Class of Anti-HIV-1 DrugsCurrent Pharmaceutical Design, 2004
- Resistance to enfuvirtide, the first HIV fusion inhibitorJournal of Antimicrobial Chemotherapy, 2004
- Injection site reactions with the HIV-1 fusion inhibitor enfuvirtideJournal of the American Academy of Dermatology, 2003
- Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumoniaAIDS, 2003
- HIV-1 drug resistance: can we overcome?Expert Opinion on Biological Therapy, 2002
- Cell surface receptors, virus entry and tropism of primate lentivirusesJournal of General Virology, 2002